-
Arthritis and Rheumatism Feb 1966
Topics: Aged; Aspirin; Blood Chemical Analysis; Female; Follow-Up Studies; Humans; Male; Middle Aged; Polymyalgia Rheumatica; Prednisone
PubMed: 4952416
DOI: 10.1002/art.1780090103 -
Joint Bone Spine Jul 2023
Topics: Humans; Polymyalgia Rheumatica; Giant Cell Arteritis; Arthritis, Rheumatoid
PubMed: 36690063
DOI: 10.1016/j.jbspin.2023.105529 -
The Indian Journal of Medical Research May 2017Polymyalgia rheumatica (PMR) is a unique disease of elderly people, traditionally diagnosed based on a clinical picture. A typical case is a combination of severe... (Review)
Review
Polymyalgia rheumatica (PMR) is a unique disease of elderly people, traditionally diagnosed based on a clinical picture. A typical case is a combination of severe musculoskeletal symptoms and systemic inflammatory response with spectacular response to corticosteroids treatment. The severity of symptoms may be surprising in older patients where immunosenescence is normally expected. However, PMR may be diagnosed in haste if there is a temptation to use this diagnosis as a shortcut to achieve rapid therapeutic success. Overdiagnosis of PMR may cause more problems compared to underdiagnosis. The 2012 PMR criteria proposed by European League against Rheumatism/American College of Rheumatology aim to minimize the role of clinical intuition and build on more objective features. However, questions arise if this is possible in PMR. This has been discussed in this review.
Topics: Adrenal Cortex Hormones; Aged; Giant Cell Arteritis; Humans; Inflammation; Medical Overuse; Polymyalgia Rheumatica; Severity of Illness Index
PubMed: 28948949
DOI: 10.4103/ijmr.IJMR_298_17 -
Radiologic Technology Mar 2021Polymyalgia rheumatica (PMR) is an inflammatory condition that occurs in older adults. Its cause is unclear but might be autoimmune, autoinflammatory, environmental, or...
Polymyalgia rheumatica (PMR) is an inflammatory condition that occurs in older adults. Its cause is unclear but might be autoimmune, autoinflammatory, environmental, or genetic. Patients with PMR have proximal joint pain and stiffness that limit mobility and decrease quality of life. Diagnosis is based on clinical symptoms and blood test results. However, blood tests often are inconclusive, and PMR symptoms overlap those of several other conditions. Medical imaging helps confirm and clarify diagnosis, assess response to treatment, and evaluate for relapses. Many patients respond to long-term, low-dosage oral glucocorticoids. This article describes the epidemiology, manifestations, diagnosis, and treatment options for PMR.
Topics: Diagnosis, Differential; Giant Cell Arteritis; Glucocorticoids; Humans; Polymyalgia Rheumatica; Quality of Life
PubMed: 33653927
DOI: No ID Found -
Recenti Progressi in Medicina May 2017Polymyalgia rheumatica (PMR) is an inflammatory disease characterized by aching and stiffness in the girdles, which affects typically people over 50 years old and could... (Review)
Review
Polymyalgia rheumatica (PMR) is an inflammatory disease characterized by aching and stiffness in the girdles, which affects typically people over 50 years old and could overlap with giant cell arteritis (GCA) in about 15-20% of cases. Although the diagnosis of PMR is usually considered straightforward, clinicians facing this disease should be aware of its atypical manifestations, which can hamper the correct identification of PMR and, conversely, should be aware of other diseases which may present with polymyalgic features. The aim of this review is to synthetize current knowledge about clinical presentations of PMR, the differential diagnoses, the relationship with cancer, the clues to the presence of a concomitant GCA, the role of ultrasonography at the onset and in the follow-up and, finally, treatment approaches. Besides evidence from the literature, this review will highlight some "tips&tricks" useful in everyday clinical practice. The awareness of the different presentations and pitfalls of PMR could improve patients' management and avoid complications consequent upon unrecognized diseases or, conversely, overtreatment.
Topics: Diagnosis, Differential; Giant Cell Arteritis; Humans; Middle Aged; Polymyalgia Rheumatica
PubMed: 28643813
DOI: 10.1701/2695.27559 -
The Medical Clinics of North America Mar 1986Polymyalgia rheumatica and temporal arteritis are a clinical syndrome and clinicopathologic entity, respectively. Polymyalgia rheumatica occurs more commonly than... (Review)
Review
Polymyalgia rheumatica and temporal arteritis are a clinical syndrome and clinicopathologic entity, respectively. Polymyalgia rheumatica occurs more commonly than temporal arteritis, with approximately half of all patients with temporal arteritis having the polymyalgia rheumatica syndrome. Both conditions are found in the population over 50 years of age and are associated with an elevated ESR. The etiology of both is unclear, although genetic, and potentially, environmental factors may play significant roles. Both conditions respond to corticosteroid therapy, but patients with temporal arteritis require significantly higher doses to control symptoms and to prevent blindness.
Topics: Adrenal Cortex Hormones; Aged; Cardiovascular Diseases; Diagnosis, Differential; Female; Giant Cell Arteritis; Headache; Humans; Male; Middle Aged; Polymyalgia Rheumatica
PubMed: 3512931
DOI: 10.1016/s0025-7125(16)30959-2 -
MMW Fortschritte Der Medizin Aug 2021
Topics: Diagnosis, Differential; Giant Cell Arteritis; Humans; Polymyalgia Rheumatica
PubMed: 34370253
DOI: 10.1007/s15006-021-0086-2 -
Best Practice & Research. Clinical... Dec 2018Polymyalgia rheumatica (PMR) and giant cell arteritis (GCA) represent a family of systemic inflammatory diseases occurring in adults aged 50 years and above. Clinical... (Review)
Review
Polymyalgia rheumatica (PMR) and giant cell arteritis (GCA) represent a family of systemic inflammatory diseases occurring in adults aged 50 years and above. Clinical presentation of PMR/GCA can be variable, making diagnosis at times challenging. There has been an increased appreciation of the role of various large-vessel imaging modalities to help confirm a diagnosis of GCA. Systemic corticosteroids (CS) remain the mainstay of treatment for both PMR and GCA, yet both relapses and CS-related side effects are common. Recent research has demonstrated efficacy of certain biologic agents in these diseases, with particular emphasis on the role of interleukin-6 (IL-6) blockade in GCA. This chapter discusses the latest updates on the diagnosis and treatment of PMR/GCA, with an emphasis on clinical care.
Topics: Adrenal Cortex Hormones; Aged; Giant Cell Arteritis; Humans; Middle Aged; Polymyalgia Rheumatica
PubMed: 31427056
DOI: 10.1016/j.berh.2019.04.006 -
Zeitschrift Fur Rheumatologie Jun 2023Polymyalgia rheumatica (PMR) is the second most frequent inflammatory rheumatic disease in old age. Remission and recurrence are frequently used as endpoints in clinical... (Review)
Review
Polymyalgia rheumatica (PMR) is the second most frequent inflammatory rheumatic disease in old age. Remission and recurrence are frequently used as endpoints in clinical trials; however, there is as yet no international consensus on the definition of these states, which limits the comparability of published studies. The PMR activity score (PMR-AS) is the only composite score specifically developed for PMR, which together with remission is used to define low, middle and high disease activity. In recent studies the PMR-AS was often used and low disease activity was established as endpoint. The most important limitation of the PMR-AS is the potential influence of the individual variables by comorbidities. The value of C‑reactive protein (CRP) and the erythrocyte sedimentation rate (ESR) are of restricted value in studies using drugs that influence the interleukin 6 (IL-6) axis. In these cases, calprotectin and osteopontin are promising alternative biomarkers, as they have already been shown to reflect disease activity independently of CRP in rheumatoid arthritis. Furthermore, imaging modalities including sonography, magnetic resonance imaging and fluorodeoxyglucose (FDG) positron emission tomography could also be helpful in monitoring disease activity; however, these techniques must first be validated in further studies. The PMR impact scale (PMR-IS) is a composite score to assess the impact of PMR on the patients; however, it has not yet been used in clinical studies. The development of additional patient reported outcomes (PRO) for PMR and the definition of standardized criteria for documentation of remission and recurrence are important questions in the future research agenda for PMR.
Topics: Humans; Polymyalgia Rheumatica; Giant Cell Arteritis; Biomarkers; Blood Sedimentation; C-Reactive Protein
PubMed: 37184675
DOI: 10.1007/s00393-023-01358-x -
Rheumatology International Nov 2015Polymyalgia rheumatica (PMR) is the most common inflammatory rheumatic disease in persons over the age of 50 years. There are many diseases which mimic PMR, for which... (Review)
Review
Polymyalgia rheumatica (PMR) is the most common inflammatory rheumatic disease in persons over the age of 50 years. There are many diseases which mimic PMR, for which reason a careful diagnostic approach is required. While it is thought to be exquisitely responsive to glucocorticosteroid therapy, many patients respond incompletely and/or develop serious side effects over the protracted disease course. Improved methods for classification and disease assessment together with standardized treatment approaches and outcome assessments can serve to improve the care of patients with this disease.
Topics: Algorithms; Critical Pathways; Decision Support Techniques; Glucocorticoids; Health Services Research; Humans; Polymyalgia Rheumatica; Predictive Value of Tests; Quality Assurance, Health Care; Quality Improvement; Quality Indicators, Health Care; Rheumatology; Risk Factors; Treatment Outcome
PubMed: 26032754
DOI: 10.1007/s00296-015-3297-y